PARIS® Test
Solid Tumors (e.g., Ovarian, Colorectal, Breast)
Commercial (LDT)Active
Key Facts
Indication
Solid Tumors (e.g., Ovarian, Colorectal, Breast)
Phase
Commercial (LDT)
Status
Active
Company
About SEngine Precision Medicine
SEngine Precision Medicine is a private, pre-revenue diagnostics company pioneering a functional precision oncology platform. Its core technology involves creating living, 3D tumor organoids from patient biopsies and screening them against a panel of oncology drugs to identify the most effective therapies. The company aims to address the high failure rate of standard genomic-based tests by providing a more direct, phenotypic readout of drug sensitivity. Its primary offering, the PARIS® test, is positioned to help oncologists make more informed, personalized treatment decisions for cancer patients.
View full company profile